一種新型快速床邊診斷檢測(cè)能夠檢測(cè)尿液中的對(duì)乙酰氨基酚。這種方法叫做Triage TOX藥物篩查，已經(jīng)獲得了美國(guó)食品藥品管理局的許可。

對(duì)乙酰氨基酚劑量過(guò)大是導(dǎo)致向美國(guó)中毒控制中心求助的首位原因，據(jù)估計(jì)在美國(guó)每年導(dǎo)致52000000中毒事件中的5％(275,000)。對(duì)乙酰氨基酚是世界范圍內(nèi)使用最廣泛的止痛劑，是100種最常見(jiàn)非處方藥和處方藥之一。盡管這種藥物有著良好的安全譜，但是在故意服用大劑量或者服用超過(guò)150-200mg/kg體重劑量的時(shí)候會(huì)發(fā)生中毒。

根據(jù)美國(guó)國(guó)家臨床生物化學(xué)學(xué)會(huì)指導(dǎo)大綱，每一例疑似故意大劑量服用患者都應(yīng)當(dāng)在1小時(shí)以?xún)?nèi)進(jìn)行對(duì)乙酰氨基酚篩查。Ken Buechler博士是Biosite公司(San Diego, CA, USA)總裁和首席科學(xué)官員，正是他開(kāi)發(fā)了這項(xiàng)檢測(cè)方法。他指出：“因?yàn)門(mén)riage TOX藥物篩查使用Triage MeterPlus平臺(tái)，這就使得在床邊檢測(cè)在大約15分鐘之內(nèi)就可以得到結(jié)果。我們相信這能夠減少檢測(cè)對(duì)乙酰氨基酚的時(shí)間。”

公司提供了3種不同的分析組合能夠涵蓋8種主要藥物。這項(xiàng)檢測(cè)在說(shuō)英語(yǔ)的國(guó)家以及經(jīng)過(guò)當(dāng)?shù)刂鞴軝C(jī)關(guān)批準(zhǔn)的國(guó)家廣泛應(yīng)用。
 
Drug Screen for Acetaminophen

A novel, rapid point-of-care (POC) diagnostic test detects acetaminophen in urine. Called Triage TOX drug screen, the test has been cleared by the U.S. Food and Drug Administration (FDA).

Overdose from acetaminophen is the leading cause for calls to the U.S. Poison Control Centers and is estimated to represent 5% (275,000) of the 5.2 million U.S. total toxic exposures annually. Acetaminophen is one of the most widely used analgesics in the world and is found in more than 100 common over-the-counter and prescription products. While the drug has an excellent safety profile, toxicity can occur after intentional overdose or acute ingestion of 150-250 mg per kg of body weight.

According to the U.S. National Academy of Clinical Biochemistry guidelines, every patient suspected of intentional drug ingestion should be screened for acetaminophen in one hour or less,” noted Ken Buechler, Ph.D., president and chief scientific officer of Biosite Incorporated (San Diego, CA, USA), which developed the test.
“Because the Triage TOX drug screen uses the Triage MeterPlus platform, which produces results in approximately 15 minutes at the point of care, we believe it can improve turnaround time for acetaminophen.”

The company is offering three different combinations of analytes to cover the eight major classes of drugs. The tests will be available in English-speaking countries worldwide and in other countries upon approval by local regulatory agencies.